A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Sponsor: Tempest Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAS7783
U.S. Govt. ID: NCT03829436
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to learn more about TPST-1120. The aims of the study are to find out if TPST-1120 can be given safely to people, to determine a safe dose of the study drug, if it is safe when given in combination with other anti-cancer drugs, what effects the drug may have, and to learn more about how the body processes the study drug. This is a first in human study, meaning the drug has never been tested with humans before. Therefore, any potential positive and negative effects of the drug are unknown. Cancers include: liver cancer.
This study is closed
Investigator
Yvonne Saenger, MD
Do You Qualify?
Do you have liver cancer? Yes No
Are you 18 years of age or older? Yes No
Are you willing to undergo extra tests and procedures, and make extra visits to the clinic? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE